Last fall, Obagi Medical officially entered the injectable space with the launch of Saypha MagIQ, its FDA-approved hyaluronic acid filler for moderate to severe nasolabial folds. The move marked a major evolution for the skin-care giant, putting it in direct competition with established filler portfolios like RHA, Restylane and Juvéderm.
This week, the brand expanded that portfolio again. Obagi announced FDA approval of Saypha ChIQ, a hyaluronic acid filler designed for cheek augmentation and correction of midface contour deficiencies in patients over 21. The new approval makes ChIQ the second injectable under Obagi’s growing aesthetics umbrella, further signaling the brand’s ambitions to become a more comprehensive player in the category.
Like MagIQ, ChIQ comes out of Obagi’s partnership with Austria-based Croma-Pharma, the global aesthetics company behind the Saypha filler line. While the brand may feel newer to U.S. injectors, Croma has been in the injectable space for decades, with more than 130 million syringes distributed across 80 countries.
At the core of ChIQ is Croma’s MACRO Core Technology, a specialized hyaluronic acid matrix designed for greater lift and structural support. The result is a filler better suited for creating shape, contour and projection in the cheeks and midface.
“The FDA approval of ChIQ is exciting because it fills an important gap,” says Austin, TX oculoplastic surgeon Sheila Barbarino, MD. “It’s a higher G-prime hyaluronic acid filler designed to provide enhanced structural support and lift. I’ve had great success with Obagi’s existing HA filler, MagIQ, which has become a true workhorse in my practice thanks to its versatility, predictability and natural-looking results. The addition of ChIQ expands the portfolio and gives providers and patients another valuable option for those seeking greater definition, contour and longevity while maintaining a refined, natural aesthetic.”
With ChIQ, Obagi continues to expand beyond skin care, building out an injectable lineup that complements the treatments many providers are already pairing with topical regimens. And in a crowded filler market, it gives injectors another option backed by decades of global experience.
